羟考酮缓释片治疗中重度癌性疼痛临床观察
摘要
目的:观察羟考酮缓释片治疗中重度癌性疼痛的疗效、不良反应及病人生活质量改变情况。方法:应用羟考酮缓释片治疗85例中重度癌性疼痛病人,根据疼痛评分调整剂量,对其疗效和不良反应进行观察和统计。采用生活质量量表EORTCQLQ-C30对癌症病人治疗前后生活质量改变情况进行评估。结果:83例病人服用羟考酮剂量10～220 mg/12 h,中度疼痛有效率为87.5%,重度疼痛有效率为88.4%,总体有效率为88.0%。病人生活质量方面,躯体功能、角色功能、认知功能以及情感功能较治疗前均有明显提高(P<0.01)。主要的不良反应为便秘41例(49.4%),其次是恶心呕吐23例(27.7%),尿潴留6例(7.2%),嗜睡5例(6%)。结论:羟考酮缓释片治疗中重度癌性疼痛安全有效,能改善病人生活质量。
引文
[1] COHEN MZ,EASLEY MK,ELLIS C,et al.Cancer pain management and the JCAHO′s pain standards:an institutional challenge[J].J Pain Symptom Manage,2003,25(6):519.
[2] SVENDSEN KB,ANDERSEN SS,ARNER S,et al.Breakthrough pain in malignant and non-malignant diseases:a review of prevalence,characteristics and mechanisms[J].Eur J Pain,2005,9(2):195.
[3] GOUDAS LC,BLOCH R,GIALELI-GOUDAS M,et al.The epidemiology of cancer pain[J].Cancer Invest,2005,23(2):182.
[4] LAURETTI GR,OLIVEIRA GM,PEREIRA NL.Comparison of sustained-release morphine with sustained-release oxycodone in advanced cancer patients[J].Br J Cancer,2003,89(11):2027.
[5] GALLEGO AO,BARON MG,ARRANZ EE.Oxycodone:a pharmacological and clinical review[J].Clin Transl Oncol,2007,9(5):298.
[6] ZHANG WZ,YU WJ,ZHAO XL,et al.Pharmacoeconomics evaluation of morphine,MS contin and oxycodone in the treatment of cancer pain[J].Asian Pac J Cancer Prev,2014,15(20):8797.
[7] NOZAKI C,SAITOH A,KAMEI J.Characterization of the antinociceptive effects of oxycodone in diabetic mice[J].Eur J Pharmacol,2006,535(1):145.
[8] NOZAKI CI,KAMEI J.Involvement of mu1-opioid receptor on oxycodone-induced anti- nociception in diabetic mice[J].Eur J Pharmacol,2007,560(2/3):160.
[9] SUNG B,LOH HH,WEI LN.Association of kappa opioid receptor mRNA upregulation in dorsal root ganglia with mechanical allodynia in mice following nerve injury[J].Neurosci Lett,2000,291(3):163.
[10] WANG YM,LIU ZW,LIU JL,et al.Efficacy and tolerability of oxycodone in moderate-severe cancerrelated pain:a metaanalysis of randomized controlled trials[J].Exp Ther Med,2012,4(2):249.
[2] SVENDSEN KB,ANDERSEN SS,ARNER S,et al.Breakthrough pain in malignant and non-malignant diseases:a review of prevalence,characteristics and mechanisms[J].Eur J Pain,2005,9(2):195.
[3] GOUDAS LC,BLOCH R,GIALELI-GOUDAS M,et al.The epidemiology of cancer pain[J].Cancer Invest,2005,23(2):182.
[4] LAURETTI GR,OLIVEIRA GM,PEREIRA NL.Comparison of sustained-release morphine with sustained-release oxycodone in advanced cancer patients[J].Br J Cancer,2003,89(11):2027.
[5] GALLEGO AO,BARON MG,ARRANZ EE.Oxycodone:a pharmacological and clinical review[J].Clin Transl Oncol,2007,9(5):298.
[6] ZHANG WZ,YU WJ,ZHAO XL,et al.Pharmacoeconomics evaluation of morphine,MS contin and oxycodone in the treatment of cancer pain[J].Asian Pac J Cancer Prev,2014,15(20):8797.
[7] NOZAKI C,SAITOH A,KAMEI J.Characterization of the antinociceptive effects of oxycodone in diabetic mice[J].Eur J Pharmacol,2006,535(1):145.
[8] NOZAKI CI,KAMEI J.Involvement of mu1-opioid receptor on oxycodone-induced anti- nociception in diabetic mice[J].Eur J Pharmacol,2007,560(2/3):160.
[9] SUNG B,LOH HH,WEI LN.Association of kappa opioid receptor mRNA upregulation in dorsal root ganglia with mechanical allodynia in mice following nerve injury[J].Neurosci Lett,2000,291(3):163.
[10] WANG YM,LIU ZW,LIU JL,et al.Efficacy and tolerability of oxycodone in moderate-severe cancerrelated pain:a metaanalysis of randomized controlled trials[J].Exp Ther Med,2012,4(2):249.